Nociceptin antagonism: Probing the receptor by N-acetyl oligopeptides

Regulatory Peptides

Volumn 122, Issue 3, 2004, Pages 199-207

  Kocsis, László ^b   Orosz, György ^b   Magyar, Anna ^b   Al Khrasani, Mahmoud ^c   Kató, Erzsébet ^c,d   Rónai, Andás Z ^c   Bes, Brice ^e   Meunier, Jean Claude ^e   Gündüz, Özge ^a   Tóth, Géza ^a   Borsodi, Anna ^a   Benyhe, Sándor ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

Author keywords

GTP S assay; Mouse vas deferens bioassay; Nociceptin; NOP receptor; Peptide antagonist; Radioligand binding

Indexed keywords

ACETYLARGINYLTYROSYLTYROSYLARGINYLISOLEUCYLLYSINAMIDE; ACETYLARGINYLTYROSYLTYROSYLARGINYLISOLEUCYLLYSINOL; ALCOHOL; DYNORPHIN[1-13]; ENDOMORPHIN 1; ENKEPHALIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HEXAPEPTIDE; KAPPA OPIATE RECEPTOR; LIGAND; N ACETYL OLIGOPEPTIDE; N ACYL HEXAPEPTIDE; N ACYL PENTAPEPTIDE; N ACYL TETRAPEPTIDE; NALOXONE; NOCICEPTIN HYDROXYPHENYLALANYLGLYCYLGLYCYLPHENYLALANYLTHREONYLGLYCYLALANYLARGINYLLYSYL SERYLALANYLARGINYLLYSYLLEUCYLALANYLASPARAGINYLGLUTAMINE; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR ANTAGONIST; OLIGOPEPTIDE; PENTAPEPTIDE; TETRAPEPTIDE; TRITIUM; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOASSAY; BRAIN MEMBRANE; BRAIN TISSUE; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; FUNCTION TEST; GENE LIBRARY; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN SYNTHESIS; RADIORECEPTOR ASSAY; RAT; RECEPTOR BINDING; STIMULATION; VAS DEFERENS;

ANIMALS; CHO CELLS; CRICETINAE; MICE; OLIGOPEPTIDES; RADIOLIGAND ASSAY; RATS; RECEPTORS, OPIOID; SIGNAL TRANSDUCTION;

EID: 20844457126     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2004.06.019     Document Type: Article

References (58)

1. Mollereau C., Parmentier M., Mailleux P., Butour J.L., Moisand C., Chalon P., et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett. 341:1994;33-38
2. Meunier J.-C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., et al. Isolation and structure of the endogenous agonist of opioid-like ORL1 receptor. Nature. 377:1995;532-535
3. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science. 270:1995;792-794
4. Henderson G., Mcknight A.T. The orphan opioid receptor and its endogenous ligand nociceptin/orphanin FQ. Trends Pharmacol. Sci. 18:1997;293-300
5. Calo' G., Guerrini R., Rizzi A., Salvadori S., Regoli D. Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br. J. Pharmacol. 129:2000;1261-1283
6. Meunier J.-C. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur. J. Pharmacol. 340:1997;1-15
7. Mogil J.S., Pasternak G.W. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol. Rev. 53:2001;381-415
8. Chen C., Xue J.C., Zhu J., Chen Y.W., Kunapuli S., Kim deRiel J., et al. Characterization of irreversible binding of β-funaltrexamine to the cloned rat m opioid receptor. J. Biol. Chem. 270:1995;17866-17870
9. 3]β-funaltrexamine covalent binding in the cloned rat mu opioid receptor. J. Biol. Chem. 271:1996;21422-21429
10. Mandyam C.D., Altememi G.F., Standifer K.M. β-Funaltrexamine inactivates ORL1 receptors in BE2-C human neuroblastoma cells. Eur. J. Pharmacol. 402:2000;R1-R3
11. Kosterlitz H.W., Watt A.J. Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnoroxymorphone (naloxone). Br. J. Pharmacol. 33:1968;266-276
12. Guerrini R., Calo' G., Rizzi A., Bigoni R., Bianchi C., Salvadori S., et al. A new selective antagonist of the nociceptin receptor. Br. J. Pharmacol. 123:1998;163-165
13. 2 is an agonist of the nociceptin (ORL1) receptor. Eur. J. Pharmacol. 349:1998;R5-R6
14. 2 in the mouse and rat colon and the mouse vas deferens. Eur. J. Pharmacol. 385:1999;217-223
15. 2 acts as a partial agonist at ORL1 receptor endogenously expressed in mouse N1E-115 neuroblastoma cells. NeuroReport. 10:1999;1127-1131
16. Dooley C.T., Spaeth C.G., Berzetei-Gurske I.P., Craymer K., Adapa I.D., Brandt S.R., et al. Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J. Pharmacol. Exp. Ther. 283:1997;735-741
17. Berger H., Albrecht E., Wallukat G., Bienert M. Antagonism by acetyl-RYYRIK-NH2 of G protein activation in rat brain preparations and of chronotropic effect on rat cardiomyocytes evoked by nociceptin/orphanin FQ. Br. J. Pharmacol. 126:1999;555-558
18. Gacel G., Fournie-Zaluski M.C., Fellion E., Roques B.P., Senault B., Lecomte J.M., et al. Conformation and biological activities of hexapeptides related to enkephalins: respective roles of the ammonium and hydroxyl groups of tyrosine. Life Sci. 24:1979;725-732
19. Rónai A.Z., Botyánszki J., Hepp J., Medzihradszky K. A novel opioid structure which accepts protonated as well as non-protonated nitrogen: a family of pure, delta receptor selective antagonists. Life Sci. 50:1992;1371-1378
20. Rónai A.Z., Botyánszky J., Magyar A., Borsodi A., Benyhe S., Medzihradszky K. Novel, delta opioid receptor-selective peptide antagonists: the demonstration of a possible opioid interaction in the absence of a protonated nitrogen and attempts to locate the protonated nitrogen site. Arch. Int. Pharmacodyn. 323:1993;114-125
21. Schiller P.W., Berezowska I., Nguyen T.M.D., Schmidt R., Lemieux C., Chung N.N., et al. Novel ligands lacking a positive charge for the d- and m-opioid receptors. J. Med. Chem. 43:2000;551-559
22. 2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists. J. Med. Chem. 44:2001;3048-3053
23. Weltrowska G., Lu Y., Lemieux C., Chung N.N., Schiller P.W. A potent cyclic opioid peptide antagonist lacking an N-terminal amino group. Biopolymers. 71:2003;P315
24. Wan Q., Murray T.F., Aldrich J.V. A novel acetylated analogue of dynorphin A-(1-11) amide as a kappa-opioid receptor antagonist. J. Med. Chem. 42:1999;3011-3013
25. Orosz G., Rónai A.Z., Bajusz S., Medzihradszky K. N-terminally protected penta- and tetrapeptide opioid antagonists based on a pentapeptide sequence found in the venom of Philippine cobra. Biochem. Biophys. Res. Commun. 202:1994;1285-1290
26. Orosz G., Rónai A.Z., Kátay E., Medzihradszky K. Kappa opioid receptor antagonists. Peptides 1994, (Proceedings of the 23rd European Peptide Symposium, Braga). 1995;607-608 Braga, ESCOM, Leiden
27. 2 that lacks the basic N-terminus. J. Med. Chem. 46:2003;1279-1282
28. 3H)-naloxone of high specific activity. J. Label. Compd. Radiopharm. 19:1982;1021-1030
29. Benyhe S., Monory K., Farkas J., Tóth G., Guerrini R., Salvadori S., et al. Nociceptin binding sites in frog (Rana esculenta) brain membranes. Biochem. Biophys. Res. Commun. 260:1999;592-596
30. Soućek M., Urban J., Saman D. Preparation of N-protected α-amino alcohols by acetoxyborohydride reduction of N-protected α-amino acid esters. Collect Czech. Chem. Commun. 55:1990;761-765
31. 2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J. Med. Chem. 41:1998;3360-3366
32. Bódi J., Süli-Vargha H., Ludányi K., Vekey K., Orosz G. New strategy for the synthesis of large peptides as applied to the c-terminal cysteine-rich 41 amino acid fragment of the mouse agouti protein. Tetrahedron Lett. 38:1997;3293-3296
33. Orosz G., Kiss L.P. Simple and efficient synthesis of 2-chlorotritylchloride resin. Tetrahedron Lett. 39:1998;3241-3242
34. Rónai A.Z., Gráf L., Székely J.I., Dunai-Kovács Z., Bajusz S. Differential behavior of LPH-(61-91)-peptide in different model systems - comparison of opioid activities of LPH-(61-91)-peptide and its fragments. FEBS Lett. 74:1977;182-184
35. Rónai A.Z., Berzétei I. Similarities and differences of opioid receptors in different isolated organs. Endorphins '78. 1979;237-257 Akademia Konyvkiado, Budapest, Hungary
36. Berzetei-Gurske I.P., Schwartz R.W., Toll L. Determination of activity for nociceptin in the mouse vas deferens. Eur. J. Pharmacol. 302:1996;R1-R2
37. Arunlakshana O., Schild H.O. Some quantitative use drug antagonists. Br. J. Pharmacol. 14:1959;48-58
38. 7, an endogenous neuropeptide, binds to multiple opioid and non-opioid sites in rat brain. J. Neurosci. Res. 48:1997;249-258
39. Stannard P., Platt M., Pilkington J. GraphPad Prism 2.01. 1995;1-373 GraphPad Softwares, San Diego, USA
40. Spetea M., Monory K., Tömböly Cs., Tóth G, Tzavara E., Benyhe S., et al. In vitro binding and signaling profile of the novel μ-opioid receptor agonist endomorphin-2 in rat brain membranes. Biochem. Biophys. Res. Commun. 250:1998;720-725
41. Guerrini R., Calo' G., Rizzi A., Bianchi C., Lazarus L.H., Salvadori S., et al. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J. Med. Chem. 40:1997;1789-1793
42. 5,6deltorphin II. Neuropeptides. 26:1994;261-265
43. Zhang S.W., Yu L. Identification of dynorphins as endogenous ligands for an opioid receptor-like orphan receptor. J. Biol. Chem. 270:1995;22772-22776
44. Salvadori S., Guerrini R., Calo' G., Regoli D. Structure-activity studies on nociceptin/orphanin FQ: from full agonist, to partial agonist, to pure antagonist. Il Farmaco. 54:1999;810-825
45. Roemer D., Buescher H.H., Hill R.C., Pless J., Bauer W., Cardinaux F., et al. A synthetic enkephalin analogue with prolonged parenteral and oral analgesic activity. Nature. 268:1977;547-549
46. Al-Khrasani M., Orosz G., Kocsis L., Farkas V., Magyar A., Lengyel I., et al. Receptor constants for endomorphin-1 and endomorphin-1-ol indicate differences in efficacy and receptor occupancy. Eur. J. Pharmacol. 421:2001;61-67
47. Montiel J.L., Cornille F., Roques B.P., Noble F. Nociceptin/orphanin FQ metabolism: role of aminopeptidase and endopeptidase 24.15. J. Neurochem. 68:1977;354-361
48. 2, a new selective nociceptin receptor antagonist. Br. J. Pharmacol. 129:2000;1183-1193
49. 2 selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain. J. Pharmacol. Exp. Ther. 294:2000;428-433
50. Ozaki S., Kawamoto H., Itoh Y., Miyaji M., Iwasawa Y., Ohta H. A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397. Eur. J. Pharmacol. 387:2000;R17-R18
51. Ozaki S., Kawamoto H., Itoh Y., Miyaji M., Azuma T., Ichikawa D., et al. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur. J. Pharmacol. 402:2000;45-53
52. Bigoni R., Calo' G., Rizzi A., Guerrini R., DeRisi C., Hashimoto Y., et al. In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist. Naunyn-Schmiedeberg's Arch. Pharmacol. 361:2000;565-568
53. Meunier J.-C. Utilizing functional genomics to identify new pain treatments: the example of nociceptin. Am. J. Pharmacogenomics. 3:2003;117-130
54. Zaveri N. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci. 73:2003;663-678
55. 2 for receptor binding. J. Pept. Sci. 8:2002;561-569
56. Judd A.K., Kaushanskaya A., Tuttle D.J., Sanchez A., Khroyan T., Polgar W., et al. N-terminal modifications leading to peptide ORL1 partial agonists and antagonists. J. Pept. Res. 62:2003;191-198
57. 2, a novel specific radioligand for the nociceptin/orphanin FQ receptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:2000;538-545
58. 2. Biochem. Biophys. Res. Commun. 310:2003;992-1001